RESHAPE HF II vs COAPT & MITRAL‑FR: Unraveling the MitraClip Debate

Welcome to IC Chat with host Dr. Ashish Pershad. In this episode we examine the controversial role of transcatheter edge-to-edge mitral valve repair for functional mitral regurgitation, focusing on the COAPT, MITRAL‑FR and the newer RESHAPE Heart Failure II trials. We summarize trial differences in patient selection, anatomy (EROA and LV volumes), outcomes (heart failure hospitalizations, quality of life and mortality), and methodological concerns that influence interpretation of RESHAPE HF II. Dr. Pershad outlines the practical implications for clinicians: selection remains critical, TEER appears to reduce heart failure admissions and improve quality of life in selected patients, but questions about mortality benefit and broad adoption persist.